ADZYNMA (ADAMTS13, recombinant-krhn) is now in stock with Orsini and ready for distribution. Orsini is the exclusive specialty pharmacy partner for...
ELK GROVE VILLAGE, Ill., Nov. 20, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy has been selected by Takeda Pharmaceuticals as the exclusive specialty...
Orsini Specialty Pharmacy has been selected by Amicus Therapeutics to dispense Pombiliti™ (cipaglucosidase alfa-atga) and Opfolda™ (miglustat), a...
There's no question that for patients coping with a rare or complex disease or a compromised immune system, COVID-19 resulted in multiple new...
Entering our third year of coping with a pandemic that continues to disrupt lives brings into ever sharper focus the multiple difficulties involved for...
While it may seem as if 30 million Americans living with more than 7,000 distinct and rare medical conditions have little in common, there is much that...
Maintaining, Monitoring, and Measuring a Smooth Patient Journey The journey of a rare disease patient is not an easy one from the start, frequently...
From filling out an insurance form to interpreting nutrition labels, a patient's understanding of what they're reading and ability to use that...
Mucopolysaccharidosis (MPS) is a rare disease in which the body is missing or does not have enough of an enzyme needed to break down long chains of...
This past year has shone a harsh light on some of our healthcare system’s most glaring flaws, illuminating a divide too deep to be ignored. Limited...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)